<DOC>
	<DOCNO>NCT00776841</DOCNO>
	<brief_summary>A Phase 1 , Randomized , Double-Blind , Placebo-Controlled , Escalating Single Multiple-Dose Study Aramchol Healthy Male Volunteers . Primary Objectives : 1 . To assess characterize safety tolerability Aramchol 16 healthy male subject single dos range 30 900 mg ( Part A ) 30 overweight , mildly hypercholesterolemic , otherwise healthy male subject receive multiple dos ( Part B ) 2 . To assess pharmacokinetics Aramchol administer dos</brief_summary>
	<brief_title>A Phase 1 Single Multiple-Dose Study Aramchol Healthy Male Volunteers</brief_title>
	<detailed_description>Number Subjects : Total : A total 46 healthy subject enrol . Part A : Sixteen ( 16 ) subject participate four , 8-person dosing period . Each cohort alternately dosed twice . Part B : Thirty ( 30 ) subject enrol two , 15-person dose-ascending cohort . Main Inclusion Criteria : Part A : Healthy male volunteer age 18-50 ( inclusive ) year provide write informed consent Part B : Mildly overweight ( 25 &lt; BMI &lt; 33 ) , fast cholesterol level 200-300 mg/ % LDL 100-180 mg/ % triglycerides &lt; 200 mg/ % , otherwise healthy male volunteer age 18-50 ( inclusive ) year , provide write informed consent</detailed_description>
	<criteria>Part A : Healthy male volunteer age 1850 ( inclusive ) year provide write informed consent Part B : Mildly overweight ( 25 &lt; BMI &lt; 33 ) , fast cholesterol level 200300 mg/ % LDL 100180 mg/ % triglycerides &lt; 200 mg/ % , otherwise healthy male volunteer age 1850 ( inclusive ) year , provide write informed consent Major History significant neurological ( include history seizure EEG abnormality ) , renal , cardiovascular ( include know structural cardiac abnormality hypertension ) , respiratory ( asthma ) , endocrinological , gastrointestinal , hematopoietic disease , neoplasm , psychological ( marked anxiety , tension agitation ) clinically significant medical disorder , investigator 's judgment contraindicate administration study medication . History drug alcohol abuse . Known allergy drug . Known allergy drug . Clinically significant abnormality find screen physical exam . Significant abnormality clinical laboratory parameter ( hematology , biochemistry , urinalysis ) determine within 40 day start study Day ( 1 ) first dose session . Parameters measure show Appendix 2 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Phase-I</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Obesity</keyword>
	<keyword>fatty liver</keyword>
	<keyword>Part A : Healthy male volunteer Part B : Mildly overweight , otherwise healthy hypercholesterolemic male volunteer</keyword>
</DOC>